FAKTOR-OPTIONSSCHEIN - NOVO-NORDISK B | Real-time Bid/Ask 06:54:42 2024-06-06 am EDT | ||
| 5.77 EUR / 5.79 EUR | 0.00% |
|
| Current month | -18.71% | ||
| 1 month | -42.77% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-06-06 | 5.65 | -2.25% |
| 24-06-05 | 5.78 | -7.67% |
| 24-06-04 | 6.26 | -9.80% |
| 24-06-03 | 6.94 | -2.39% |
| 24-05-31 | 7.11 | -2.74% |
Delayed Quote Börse Stuttgart
Last update June 06, 2024 at 04:27 am EDT
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | Morgan Stanley |
| WKN | MG1SF3 |
| ISIN | DE000MG1SF33 |
| Date issued | 2024-04-05 |
| Strike | 1,170 kr |
| Maturity | Unlimited |
| Parity | 4.68 : 1 |
| Emission price | 10 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 10.98 € |
|---|---|
| Lowest since issue | 5.65 € |
| Spread | 0.02 € |
| Spread % | 0.35% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
936.2
DKK
Average target price
920
DKK
Spread / Average Target
-1.73%
- Stock Market
- Certificates
- Certificat
